Skip to content
Peptide research

PNC-27

Category
Specialized Research
Administration routes
Injectable
Regulatory status
Not FDA-approved

What it is

PNC-27 is a synthetic p53-derived peptide marketed as an experimental cancer treatment said to rupture tumor cells while sparing normal ones. The case rests on low-confidence cell and mouse studies (leukemia, ovarian lines), with no human trials and no human safety data. The FDA has warned about contaminated, unapproved versions, and interactions with chemotherapy are unknown. Not an approved drug, it circulates only as unregulated research-grade product.

Read Full record

Studied uses & evidence

Studied uses(7)

  • Selective cancer cell killing via membrane-bound HDM-2 targeting

    Low

    Selective killing shown in vitro across many cancer types; mechanism defined, no human trials yet.

  • Transmembrane pore formation causing rapid necrotic cancer cell death

    Low

    Cell-culture studies show rapid pore-based cell death within hours; mechanism not yet confirmed independently.

  • Efficacy against leukemia cells with no harm to normal hematopoietic cells

    Low

    Lab and mouse studies show leukemia cell death while sparing normal blood cells; no human trials.

Evidence limits

Evidence Level
Preclinical

PNC-27 has strong preclinical data demonstrating selective cancer cell killing through a novel mechanism (binding to membrane-bound HDM-2 and inducing transmembrane pore formation). The mechanism is well-characterized at the structural, biochemical, and cellular levels. In vitro efficacy has been shown in pancreatic cancer, breast cancer, melanoma, multiple leukemia subtypes, colon cancer (including cancer stem cells), patient-derived ovarian cancer (including chemotherapy-resistant lines), and cervical cancer. In vivo results in nude mice show tumor eradication without normal tissue damage. However, translation to humans remains entirely theoretical. No human clinical trials have been conducted, no IND has been filed with the FDA, and the FDA has issued warnings against using PNC-27 products marketed as cancer treatments. The lack of human pharmacokinetics, biodistribution, immunogenicity, and systemic safety data represents a critical gap that must be addressed before clinical application.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Risk summary(7)

Risks = level of concern: High · Moderate · Low · Theoretical

  • No established human safety profile

    High
  • FDA warning — contaminated and unapproved products

    High
  • Unregulated product quality from research-grade sources

    High
  • Potential for serious adverse events

    Moderate
  • Possible immunogenicity

    Theoretical
  • Unknown interactions with chemotherapy and immunotherapy

    Moderate
  • Contraindicated in pregnancy, lactation, and severe immune disorders

    Moderate
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.